CA3147789A1 - Compose agoniste du recepteur thr-.beta. heterocyclique, son procede de preparation et son utilisation - Google Patents

Compose agoniste du recepteur thr-.beta. heterocyclique, son procede de preparation et son utilisation Download PDF

Info

Publication number
CA3147789A1
CA3147789A1 CA3147789A CA3147789A CA3147789A1 CA 3147789 A1 CA3147789 A1 CA 3147789A1 CA 3147789 A CA3147789 A CA 3147789A CA 3147789 A CA3147789 A CA 3147789A CA 3147789 A1 CA3147789 A1 CA 3147789A1
Authority
CA
Canada
Prior art keywords
group
compound
pharmaceutically acceptable
acceptable salt
isomer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3147789A
Other languages
English (en)
Inventor
Shanghai Yu
Ben Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hepagene Therapeutics HK Ltd
Original Assignee
Hepagene Therapeutics HK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CN202010112084.3A external-priority patent/CN112457346B/zh
Application filed by Hepagene Therapeutics HK Ltd filed Critical Hepagene Therapeutics HK Ltd
Priority claimed from PCT/CN2020/121801 external-priority patent/WO2021032218A1/fr
Publication of CA3147789A1 publication Critical patent/CA3147789A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne un composé chimique représenté par la formule (I) et un isomère de celui-ci ou un sel pharmaceutiquement acceptable de celui-ci. Ce composé améliore l'activité agoniste du THR-? tout en améliorant la sélectivité pour le THR-?, ce qui permet d'améliorer la qualité pharmaceutique.
CA3147789A 2020-02-24 2020-10-19 Compose agoniste du recepteur thr-.beta. heterocyclique, son procede de preparation et son utilisation Pending CA3147789A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202010112084.3 2020-02-24
CN202010112084.3A CN112457346B (zh) 2019-08-19 2020-02-24 一种并环THRβ受体激动剂化合物及其制备方法和用途
PCT/CN2020/121801 WO2021032218A1 (fr) 2019-08-19 2020-10-19 COMPOSÉ AGONISTE DU RÉCEPTEUR THR-β HÉTÉROCYCLIQUE, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION

Publications (1)

Publication Number Publication Date
CA3147789A1 true CA3147789A1 (fr) 2021-02-25

Family

ID=80856182

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3147789A Pending CA3147789A1 (fr) 2020-02-24 2020-10-19 Compose agoniste du recepteur thr-.beta. heterocyclique, son procede de preparation et son utilisation

Country Status (3)

Country Link
JP (1) JP2022544943A (fr)
KR (1) KR20220134512A (fr)
CA (1) CA3147789A1 (fr)

Also Published As

Publication number Publication date
JP2022544943A (ja) 2022-10-24
KR20220134512A (ko) 2022-10-05

Similar Documents

Publication Publication Date Title
CN113194958B (zh) THRβ受体激动剂化合物及其制备方法和用途
EP2603503B1 (fr) Mésylate de dabigatran étexilate, ses formes solides et leurs procédés de préparation
US20090131677A1 (en) Substituted beta-phenyl-alpha-hydroxy-propanoic acid, synthesis method and use thereof
EP3359528B1 (fr) Agonistes de ppar, composés, compositions pharmaceutiques, et procédés d'utilisation de ceux-ci.
KR20150132146A (ko) 헤모글로빈 조정을 위한 화합물 및 이의 용도
JPH057386B2 (fr)
WO2017201313A1 (fr) Nouveaux découplants mitochondriaux pour le traitement de maladies métaboliques et du cancer
KR20130099110A (ko) 치환 아미드 화합물
CN108349911A (zh) 可释放一氧化氮的前药分子
AU2020334943A1 (en) Heterocyclic THR-β receptor agonist compound and preparation method and use therefor
US20180265466A1 (en) Pyrrole compound, compositions and process for preparation thereof
CA3147789A1 (fr) Compose agoniste du recepteur thr-.beta. heterocyclique, son procede de preparation et son utilisation
JPS6110554A (ja) 置換−３−（２，３−ジヒドロ−１ｈ−インデン−５−イル）−４−ヒドロキシ−１ｈ−ピロ−ル−２，５−ジオン，その同族体及び塩
CN112457346B (zh) 一种并环THRβ受体激动剂化合物及其制备方法和用途
EP2767533B1 (fr) Dérivé de butylphtalide et son procédé de préparation et son utilisation
US10577379B1 (en) Fenofibric acid salt with berberine or its analogues, crystalline forms, methods of preparation, and applications thereof
CA3147471A1 (fr) Inhibiteurs de l'atgl humain
JP2022504707A (ja) 芳香族化合物およびその医薬用途
CN111393421A (zh) 丁烯酸内酯类衍生物及其制备方法与应用
WO2022048620A1 (fr) Polymorphes de formes cristallines de 3, 10-diméthoxy-5, 8, 13, 13a-tétrahydro-6h-isoquinolino [3, 2-a] isoquinolin-9-yl 3-fluorobenzènesulfonate et leurs sels
KR102437095B1 (ko) 캐스파제 저해제의 프로드럭
US9512095B2 (en) Polymorph forms of desazadesferrithiocin analogs
US11884627B2 (en) Compounds and compositions for treating conditions associated with LPA receptor activity
US20210114975A1 (en) Therapeutic compound and methods
US20060154970A1 (en) Alanines compounds, method of preparing them and their use